SLC6A3 and Splenomegaly: Although we did not test PI3K functional status in our patient, it can be speculated that PI3K inhibition favored the control of our patient’s immunodysregulatory features, as indicated by the resolution of splenomegaly, a decrease in B220-positive DN T-cell count, and DAT negativization under sirolimus treatment.